Angiotensin-(1-7) Contributes to the Antihypertensive Effects of Blockade of the Renin-Angiotensin System

Hypertension

Volumn 31, Issue 1, 1998, Pages 356-361

  Iyer, Shridhar N ^a   Ferrario, Carlos M ^a   Chappell, Mark C ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN II (1 7); ANGIOTENSIN II (1-7); ANGIOTENSIN II, SAR(1) THR(8); ANGIOTENSIN II, SAR(1)-THR(8)-; ANTIHYPERTENSIVE AGENT; BRADYKININ; CGS 24592; CYCLO(TRP ASP PRO VAL LEU); CYCLO(TRP-ASP-PRO-VAL-LEU); CYCLOPEPTIDE; DIPEPTIDE; DRUG DERIVATIVE; ICATIBANT; LISINOPRIL; LOSARTAN; MEMBRANE METALLOENDOPEPTIDASE; N (1 CARBOXY 3 PHENYLPROPYL)PHENYLALANYLISOSERINE; PEPTIDE FRAGMENT; PHENYLALANINE; PHOSPHONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANIMAL; ARTICLE; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG EFFECT; HEART RATE; HYPERTENSION; KINETICS; MALE; PATHOPHYSIOLOGY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME INHIBITION; MEAN ARTERIAL PRESSURE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; RECEPTOR BLOCKING;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRADYKININ; DIPEPTIDES; HEART RATE; HYPERTENSION; KINETICS; LISINOPRIL; LOSARTAN; MALE; NEPRILYSIN; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; PHENYLALANINE; PHOSPHONIC ACIDS; PROTEASE INHIBITORS; RATS; RATS, INBRED SHR; RENIN-ANGIOTENSIN SYSTEM;

EID: 0031601350     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.31.1.356     Document Type: Article

References (37)

1. Moriguchi A, Tallant EA, Matsumura K, et al. Opposing actions of angiotensin-(1-7) and angiotensin II in the brain of transgenic hypertensive rats. Hypertension. 1995;25:1260-1265.
2. DelliPizzi A, Hilchey SD, Bell-Quilley CP. Natriuretic actions of angiotensin-(1-7). Br J Pharmacol. 1994;111:1-3.
3. 2 release. Hypertension. 1995;25:1238-1244.
4. Handa RK, Ferrario, CM, Strandhoy JW. Renal actions of angiotensin-(1-7) in vivo and in vitro studies. Am J Physiol. 1996;270:F141-F147.
5. Osei SY, Ahima RS, Minkes RK, Weaver JP, Khosla MC, Kadowitz PJ. Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur J Pharmacol. 1993;234:35-42.
6. Porsti I, Bara AT, Busse R, Hecker M. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol. 1994;111:652-654.
7. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27:523-528.
8. Paula RD, Lima CV, Khosla MC, Santos RAS. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension. 1995;26:1154-1159.
9. Abbas A, Gorelik G, Carbini LA, Scicli AG. Angiotensin-(1-7) induces bradykinin-mediated hypotensive responses in anesthetized rats. Hypertension. 1997;30:217-221.
10. Li P, Chappell MC, Ferrario CM, Brosnihan KB. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997;29:394-400.
11. Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension. 1997. In press.
12. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counter-regulatory actions of angiotensin-(1-7). Hypertension. 1997;30:535-541.
13. Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties, and enzymatic activity of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci. 1993;52:1461-1480.
14. Yamamoto K, Chappell MC, Brosnihan KB, Ferrario CM. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension. 1992;19:692-696.
15. Chappell MC, Pirro NT, Ferrario CM. Angiotensin-(1-7) exhibits high affinity towards angiotensin converting enzyme and is converted to angiotensin-(1-5). Hypertension. 1997;30:512. Abstract.
16. Lawrence AC, Clark IJ, Campbell DJ. Increased angiotensin-(1-7) in hypophysial-portal plasma of conscious sheep. Neuroendocrinology. 1992;55:105-114.
17. Campbell DJ, Lawrence AC, Towne A, Kladis A, Valentijn AJ. Differential regulation of angiotensin peptides in plasma and kidney of the rat. Hypertension. 1991;18:763-773.
18. Kohara K, Brosnihan KB, Chappell MC, Khosla MC, Ferrario CM. Angiotensin-(1-7): a member of circulating angiotensin peptides. Hypertension. 1991;17:131-138.
19. Kohara, K, Brosnihan KB, Ferrario CM. Angiotensin-(1-7) in the spontaneously hypertensive rat. Peptides. 1993;14:883-891.
20. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens. 1996;14:799-805.
21. De Lombaert S, Erion MD, Tan J, et al. N-phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors. J Med Chem. 1994;37:498-511.
22. Kohara K, Tabuchi Y, Senanayake P, Brosnihan KB, Ferrario CM. Reassessment of plasma angiotensins measurement: effects of protease inhibitors and sample handling procedures. Peptides. 1991;12:1135-1141.
23. Tomoda F, Lew RA, Smith AI, Madden AC, Evans RG. Role of bradykinin receptors in the renal effects of inhibition of angiotensin converting enzyme and endopeptidases 24.11 and 24.15 in conscious rabbits. Hypertens Res. 1996;19:229-238.
24. Bao G, Qadri F, Stauss B, Stauss H, Gohlke P, Unger T. HOE 140, a new highly potent and long-acting bradykinin antagonist in conscious rats. Eur J Pharmacol. 1991;200:179-182.
25. Bazil MK, Lappe RW, Webb RL. Pharmacological characterization of an endothelin A (ETA) receptor antagonist in conscious rats. J Cardiovasc Pharmacol. 1992;20:940-948.
26. Ihara M, Noguchi K, Saeki T, et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 1991;50:247-255.
27. Senanayake PD, Moriguchi A, Kumagai H, Ganten D, Ferrario CM, Brosnihan KB. Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats. Peptides. 1994;15:919-926.
28. Nakamoto H, Ferrario CM, Fuller SB, Robaczwski DL, Winicov E, Dean RH. Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension. Hypertension. 1995;25:796-802.
29. Sybertz EJ, Chiu PJS, Vemulapalli S, et al. SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in deoxycorticosterone acetate-sodium hypertensive rats. J Pharmacol Exp Ther. 1989;250:624-631.
30. Tallant EA, Ferrario CM. Biology of angiotensin II receptor inhibition with a focus on losartan: a new drug for the treatment of hypertension. Exp Opin Invest Drugs. 1996;5:1201-1214.
31. Ye M, Flores G, Bade D. Angiotensin II and angiotensin-(1-7) effects on free cytosolic sodium, intracellular pH, and the Na+-H+ antiporter in vascular smooth muscle. Hypertension. 1996;27:72-78.
32. Chappell MC, Jacobsen DW, Tallant EA. Characterization of angiotensin II receptor subtypes in pancreatic acinar AR42J cells. Peptides. 1995;16:741-747.
33. Tallant EA, Lu X, Weiss RB, Chappell MC, Ferrario CM. Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. Hypertension. 1997;29:388-392.
34. Nickenig G, Geisen G, Vetter H, Sachinidis A. Characterization of angiotensin receptors on human skin fibroblasts. J Mol Med. 1997;75:217-222.
35. Roques BP, Noble F, Crine P, Fournie-Zaluski M-C. Inhibitors of neprilysin: design, pharmacological and clinical applications. Methods Enzymol. 1995;248:263-283.
36. Pham I, Levy B, Fournie-Zaluski MC, Poitevin P, Roques BP, Michel JB. Acute hemodynamic effects of combined inhibition of neutral endopeptidase and angiotensin converting enzyme in spontaneously hypertensive rats. Fundam Clin Pharmacol. 1995;9:153-160.
37. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counter-regulatory actions of angiotensin-(1-7). Hypertension. 1997;30:535-541.